Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NASDAQ:IKT NASDAQ:IMMP NASDAQ:NLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$2.80-2.6%$2.42$1.29▼$3.23$264.27M2.79420,222 shs164,040 shsIKTInhibikase Therapeutics$1.94-4.7%$1.84$1.33▼$2.27$255.54M0.961.54 million shs144,782 shsIMMPPrima BioMed$0.45+2.0%$0.89$0.29▼$3.53$66.61M2.2410.49 million shs772,285 shsNLTXNeoleukin Therapeutics$30.78-1.5%$23.26$2.03▼$14.36$289.27M1.1150,104 shs168,844 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen-1.03%+5.90%+11.24%+63.07%+127.78%IKTInhibikase Therapeutics-1.46%+6.28%+19.41%+26.88%+202,999,900.00%IMMPPrima BioMed-0.65%+1.58%+41.52%-84.06%-76.05%NLTXNeoleukin Therapeutics0.00%+14.64%+51.03%+74.69%+108.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$2.80-2.6%$2.42$1.29▼$3.23$264.27M2.79420,222 shs164,040 shsIKTInhibikase Therapeutics$1.94-4.7%$1.84$1.33▼$2.27$255.54M0.961.54 million shs144,782 shsIMMPPrima BioMed$0.45+2.0%$0.89$0.29▼$3.53$66.61M2.2410.49 million shs772,285 shsNLTXNeoleukin Therapeutics$30.78-1.5%$23.26$2.03▼$14.36$289.27M1.1150,104 shs168,844 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen-1.03%+5.90%+11.24%+63.07%+127.78%IKTInhibikase Therapeutics-1.46%+6.28%+19.41%+26.88%+202,999,900.00%IMMPPrima BioMed-0.65%+1.58%+41.52%-84.06%-76.05%NLTXNeoleukin Therapeutics0.00%+14.64%+51.03%+74.69%+108.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 2.75Moderate Buy$5.0078.25% UpsideIKTInhibikase Therapeutics 3.13Buy$5.50182.78% UpsideIMMPPrima BioMed 1.75Reduce$5.501,103.50% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IMMP, CGEN, NLTX, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026IKTInhibikase Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CGENCompugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026CGENCompugen Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.003/25/2026CGENCompugen Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/13/2026IMMPPrima BioMed Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold3/13/2026IMMPPrima BioMed Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Neutral$7.00 ➝ $1.003/13/2026IMMPPrima BioMed Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/4/2026IKTInhibikase Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/4/2026IKTInhibikase Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.002/23/2026IKTInhibikase Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy2/23/2026IMMPPrima BioMed Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$10.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$72.76M3.65$0.36 per share7.76$1.09 per share2.57IKTInhibikase TherapeuticsN/AN/AN/AN/A$2.30 per shareN/AIMMPPrima BioMed$6.69M10.07N/AN/A$0.63 per share0.73NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen$35.34M$0.377.58N/AN/A48.57%55.68%29.68%5/18/2026 (Estimated)IKTInhibikase Therapeutics-$48.26M-$0.48N/AN/AN/AN/A-46.90%-43.48%N/AIMMPPrima BioMed-$39.78MN/AN/AN/AN/AN/AN/AN/AN/ANLTXNeoleukin Therapeutics-$57.56M-$3.11N/AN/AN/AN/A-37.22%-30.91%N/ALatest IMMP, CGEN, NLTX, and IKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026CGENCompugen-$0.07N/AN/AN/A$1.57 millionN/A3/26/2026Q4 2025IKTInhibikase Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A3/2/2026Q4 2025CGENCompugen$0.05$0.60+$0.55$0.60$14.30 million$67.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A6.566.56IKTInhibikase TherapeuticsN/A21.7021.70IMMPPrima BioMedN/A2.97N/ANLTXNeoleukin TherapeuticsN/A15.3315.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%IKTInhibikase Therapeutics3.81%IMMPPrima BioMed2.32%NLTXNeoleukin Therapeutics52.37%Insider OwnershipCompanyInsider OwnershipCGENCompugen9.50%IKTInhibikase Therapeutics7.30%IMMPPrima BioMed3.07%NLTXNeoleukin Therapeutics1.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7094.55 million85.57 millionOptionableIKTInhibikase Therapeutics6132.06 million122.42 millionN/AIMMPPrima BioMed2,021147.37 million142.85 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataIMMP, CGEN, NLTX, and IKT HeadlinesRecent News About These CompaniesNeoleukin Therapeutics (NASDAQ:NLTX) Stock Price Up 0.3% - Still a Buy?April 29, 2026 | marketbeat.com(NGNE) Proactive StrategiesOctober 18, 2024 | news.stocktradersdaily.comNNeurogene concludes merger deal with Neoleukin TherapeuticsDecember 20, 2023 | pharmaceutical-technology.comPIs Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?December 20, 2023 | finance.yahoo.comNeoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitDecember 14, 2023 | finance.yahoo.comNeoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and DatesDecember 4, 2023 | benzinga.comPre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…October 5, 2023 | markets.businessinsider.comNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 26, 2023 | finanznachrichten.deNeoleukin Thera (NASDAQ: NLTX) should be up 500% - it’s actually up 7%September 26, 2023 | dhakatribune.comDNeoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comInvesting in Neoleukin Therapeutics Inc. [NLTX]: What You Must KnowAugust 21, 2023 | knoxdaily.comKNeoleukin Therapeutics Recent Insider ActivityAugust 18, 2023 | benzinga.comBAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics IncAugust 18, 2023 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCUAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTXAugust 1, 2023 | markets.businessinsider.comRedmile Group, LLC Boosts Stake in Neoleukin Therapeutics IncJuly 28, 2023 | finance.yahoo.comMoore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law FirmJuly 26, 2023 | benzinga.comAnalysts review Neoleukin Therapeutics Inc.’s ratingJuly 26, 2023 | knoxdaily.comKALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, NLTX, HCCI, CCFJuly 24, 2023 | kentuckytoday.comKBaker Bros. Advisors Now Owns 19.99% of Neoleukin TherapeuticsJuly 24, 2023 | 247wallst.comAn Analysis of Neoleukin Therapeutics Inc. (NLTX)’s Potential Price GrowthJuly 19, 2023 | knoxdaily.comKNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMMP, CGEN, NLTX, and IKT Company DescriptionsCompugen NASDAQ:CGEN$2.80 -0.08 (-2.61%) As of 12:50 PM Eastern This is a fair market value price provided by Massive. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Inhibikase Therapeutics NASDAQ:IKT$1.94 -0.10 (-4.68%) As of 12:48 PM Eastern This is a fair market value price provided by Massive. Learn more.Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.Prima BioMed NASDAQ:IMMP$0.45 +0.01 (+2.01%) As of 12:49 PM Eastern This is a fair market value price provided by Massive. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Neoleukin Therapeutics NASDAQ:NLTX$30.78 -0.48 (-1.54%) As of 05/8/2026Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
